287 related articles for article (PubMed ID: 23160423)
1. Enhancing clinical trials in neurodegenerative disorders: lessons from amyotrophic lateral sclerosis.
Gladman M; Cudkowicz M; Zinman L
Curr Opin Neurol; 2012 Dec; 25(6):735-42. PubMed ID: 23160423
[TBL] [Abstract][Full Text] [Related]
2. Can selection of rapidly progressing patients shorten clinical trials in amyotrophic lateral sclerosis?
de Carvalho M; Swash M
Arch Neurol; 2006 Apr; 63(4):557-60. PubMed ID: 16606769
[TBL] [Abstract][Full Text] [Related]
3. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
Miller RG; Mitchell JD; Lyon M; Moore DH
Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
[TBL] [Abstract][Full Text] [Related]
4. Improving efficiency of ALS clinical trials using lead-in designs.
Moore DH; Miller RG
Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Sep; 5 Suppl 1():57-60. PubMed ID: 15512875
[TBL] [Abstract][Full Text] [Related]
5. Amyotrophic lateral sclerosis: an update.
de Carvalho M; Swash M
Curr Opin Neurol; 2011 Oct; 24(5):497-503. PubMed ID: 21725240
[TBL] [Abstract][Full Text] [Related]
6. A placebo arm is not always necessary in clinical trials of amyotrophic lateral sclerosis.
Gordon PH
Muscle Nerve; 2009 Jun; 39(6):858-60. PubMed ID: 19382169
[TBL] [Abstract][Full Text] [Related]
7. A retrospective review of the progress in amyotrophic lateral sclerosis drug discovery over the last decade and a look at the latest strategies.
DeLoach A; Cozart M; Kiaei A; Kiaei M
Expert Opin Drug Discov; 2015 Oct; 10(10):1099-118. PubMed ID: 26307158
[TBL] [Abstract][Full Text] [Related]
8. Selecting promising ALS therapies in clinical trials.
Cheung YK; Gordon PH; Levin B
Neurology; 2006 Nov; 67(10):1748-51. PubMed ID: 17130405
[TBL] [Abstract][Full Text] [Related]
9. Emerging drugs for amyotrophic lateral sclerosis.
Habib AA; Mitsumoto H
Expert Opin Emerg Drugs; 2011 Sep; 16(3):537-58. PubMed ID: 21806316
[TBL] [Abstract][Full Text] [Related]
10. Advances in stem cell research for Amyotrophic Lateral Sclerosis.
Papadeas ST; Maragakis NJ
Curr Opin Biotechnol; 2009 Oct; 20(5):545-51. PubMed ID: 19819686
[TBL] [Abstract][Full Text] [Related]
11. Drug therapy for amyotrophic lateral sclerosis: Where are we now?
Carter GT; Krivickas LS; Weydt P; Weiss MD; Miller RG
IDrugs; 2003 Feb; 6(2):147-53. PubMed ID: 12789618
[TBL] [Abstract][Full Text] [Related]
12. [Biomarkers for amyotrophic lateral sclerosis].
Tokuda T
Brain Nerve; 2012 May; 64(5):515-23. PubMed ID: 22570065
[TBL] [Abstract][Full Text] [Related]
13. Clinical trials in ALS: what did we learn from recent trials in humans?
Meininger V
Neurodegener Dis; 2005; 2(3-4):208-14. PubMed ID: 16909027
[TBL] [Abstract][Full Text] [Related]
14. Toward more efficient clinical trials for amyotrophic lateral sclerosis.
Cudkowicz ME; Katz J; Moore DH; O'Neill G; Glass JD; Mitsumoto H; Appel S; Ravina B; Kieburtz K; Shoulson I; Kaufmann P; Khan J; Simpson E; Shefner J; Levin B; Cwik V; Schoenfeld D; Aggarwal S; McDermott MP; Miller RG
Amyotroph Lateral Scler; 2010 May; 11(3):259-65. PubMed ID: 19961263
[TBL] [Abstract][Full Text] [Related]
15. Clinical and experimental neuroprotection in neurodegenerative diseases is a therapeutic option for the future of amyotrophic lateral sclerosis (ALS). Preface.
Ludolph AC; Drory VE
J Neurol; 2000 Dec; 247 Suppl 6():VI/1. PubMed ID: 19714407
[No Abstract] [Full Text] [Related]
16. ALS biomarkers for therapy development: State of the field and future directions.
Benatar M; Boylan K; Jeromin A; Rutkove SB; Berry J; Atassi N; Bruijn L
Muscle Nerve; 2016 Feb; 53(2):169-82. PubMed ID: 26574709
[TBL] [Abstract][Full Text] [Related]
17. Designing clinical trials in amyotrophic lateral sclerosis.
Shefner JM
Phys Med Rehabil Clin N Am; 2008 Aug; 19(3):495-508, ix. PubMed ID: 18625412
[TBL] [Abstract][Full Text] [Related]
18. Collaborative National ALS Study Group. Patient orientated research and clinical trials.
Bradley WG
J Neurol Sci; 2006 Mar; 242(1-2):71-4. PubMed ID: 16386274
[TBL] [Abstract][Full Text] [Related]
19. A review of the potential role of nano-enabled drug delivery technologies in amyotrophic lateral sclerosis: lessons learned from other neurodegenerative disorders.
Mazibuko Z; Choonara YE; Kumar P; Du Toit LC; Modi G; Naidoo D; Pillay V
J Pharm Sci; 2015 Apr; 104(4):1213-29. PubMed ID: 25559087
[TBL] [Abstract][Full Text] [Related]
20. Addressing heterogeneity in amyotrophic lateral sclerosis CLINICAL TRIALS.
Goyal NA; Berry JD; Windebank A; Staff NP; Maragakis NJ; van den Berg LH; Genge A; Miller R; Baloh RH; Kern R; Gothelf Y; Lebovits C; Cudkowicz M
Muscle Nerve; 2020 Aug; 62(2):156-166. PubMed ID: 31899540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
